Market

To offer bioequivalence studies for generic pharma and late phase patient-based clinical studies for research-based companies

The Mumbai market grew the highest at 24.3 per cent followed by Vidarbha at 21.3 per cent

It will be held in Mumbai from October 16-18, 2014; the theme for the event will be ‘The Future of Indian Healthcare: Patients,…

IDMA briefing on impact of Mumbai HC order quashing FSSAI advisory

With a 5.7 per cent growth in sales in 2013, Boehringer Ingelheim (BI) ranks seventh among its global peers but has a long way to…

The investment will fund the launch of a range of drugs in the areas of respiratory, oncology and antiretroviral medicines

Creates an innovative new model in speciality pharma leadership

The programme combines grants portfolio with annual €20 million investment to advance innovation and medical education

Donates 500 tubes of REGEN-D to AP CM’s Relief Fund

Telmisartan is Glenmark’s generic version of Boehringer Ingelheim’s Micardis